How much funding has HY2CARE raised?

HY2CARE has raised $4.9M in total funding, most recently a Series B round.

Who are HY2CARE's investors?

HY2CARE's investors include European Innovation Council Fund.

Where is HY2CARE headquartered?

HY2CARE is headquartered in Geleen, Netherlands.

What industry is HY2CARE in?

HY2CARE operates in Biotech, Healthcare.

HY2CARE

Hydrogel implant for enabling cartilage recovery

Geleen, Netherlands · Founded 2014 · $4.9M raised

Biotech

Healthcare

Headquarters: Geleen
Employees: 1–10
Founded: 2014
Business Model: B2B

Website: hy2care.com
Total Funding: $4.9M
Last Round: $4.9M Series BMay 2025
Rounds: 1

About

Hy2Care is a Dutch medtech company and spin-off of the Tech Med Centre at the University of Twente, focused on developing innovative hydrogel-based implants for repairing damaged cartilage. Founded in 2014 by Prof. Marcel Karperien and Dr. Sanne Both, the company's flagship product is the CartRevive® hydrogel implant — a bioresorbable, in-situ gelating hydrogel designed for the arthroscopic treatment of cartilage defects in joints, particularly the knee. The CartRevive® is composed of natural, joint-tissue-mimicking polymers that create a natural scaffold for the patient's own cells to regenerate new cartilage matrix, enabling functional repair without damaging surrounding tissue. Hy2Care's headquarters and laboratory are located at the Brightlands Chemelot Campus in Geleen, Limburg, a key innovation hub in the Netherlands.

Summary

HY2CARE is a Biotech company based in Geleen, Netherlands, founded in 2014. It has raised $4.9M in total across 1 round, most recently a $4.9M Series B round in May 2025. Investors include European Innovation Council Fund.